This resource was selected by SMI Adviser content partners and approved by the SMI Adviser clinical expert team for inclusion in the knowledge base.
This report summarizes the consensus from a roundtable that focused on defining and identifying treatment-resistant schizophrenia (TRS), pathways to treatment resistance, current treatments, unmet needs, and disease burden.